An interventional study of Core behavioral weight loss intervention and Self-monitoring diet in Obesity, Overweight and Weight Loss, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Obesity by Stanford University — 8 open to participants now, 10 under way, none of them phase 3. Obesity · Stanford University.
Among the 61 studies in Obesity by Stanford University, this one is the 22nd largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2023, is one of 42 with no phase, and was the 51st registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →8 of the 61 studies in Obesity by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 10–15
Stanford University · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Stanford University · Sites in United States
Ages 10–18
Stanford University · Sites in United States
Ages 18–70 · Healthy volunteers
Stanford University · Sites in United States
Ages 35–65 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 2 · Phase 4 1
First in 1982; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 102 across the 53 interventional studies, 115 across the 4 observational. Of the 47 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
2 of the studies in Obesity by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT07032571Stanford UniversityReset: Enhancing Weight Loss in a Digital Intervention | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 61 studies in Obesity by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This optimization trial will examine three tracking (or "self-monitoring") strategies for weight loss -- tracking dietary intake, steps, and/or body weight -- all delivered through digital health tools. The purpose of the study is to evaluate the combination of these strategies that maximizes 6-month weight loss in the context of a standalone digital health intervention for adults with overweight or obesity.
The investigators will recruit 176 total participants to the trial. Recruitment will occur through remote channels. Interested individuals will be directed to an online screening questionnaire; those who are eligible will then be invited to attend an initial remote session with study personnel to ensure interest and eligibility in the study. The weight loss intervention will last 6 months, and all participants will receive a "core" treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely. Depending on which group participants are assigned to in the study, some individuals will be asked to track their dietary intake, their steps, and/or their body weight via digital tools. All study tasks will occur remotely, thus, participants never need to come in-person for any intervention or assessment tasks.
The investigators will use the Multiphase Optimization Strategy (MOST) framework to identify the most effective combination of self-monitoring strategies. The factorial design will allow the research team to determine the unique and combined impact of each self-monitoring component on weight change. The primary outcome is weight change from baseline to 6 months. The research team will also assess self-monitoring engagement over 6 months and its association with weight change. To complement the main trial, the research team will also randomize half of participants to receive an interactive orientation video, in order to assess its impact on trial retention at 6 months. Overall, the information gathered from this trial will enable the construction of an optimized digital health intervention for weight loss that can be delivered remotely, which, if found to be effective, could have high potential for scalability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Core Only
Behavioral: Core behavioral weight loss intervention
Core + Track Weight
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring weight
Core + Track Steps
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring steps
Core + Track Diet
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet
Core + Track Weight + Track Steps
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring weight · Behavioral: Self-monitoring steps
Core + Track Weight + Track Diet
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet · Behavioral: Self-monitoring weight
Core + Track Steps + Track Diet
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet · Behavioral: Self-monitoring steps
Core + Track Weight + Track Steps + Track Diet
Behavioral: Core behavioral weight loss intervention · Behavioral: Self-monitoring diet · Behavioral: Self-monitoring weight · Behavioral: Self-monitoring steps
All participants will receive a 6-month "core" behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.
Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
Body Weight Change From Baseline to 6 Months
change in weight from baseline to 6-month followup (in kg); assessed objectively via e-scale
Time frame: baseline, 6 months
Body Weight From Baseline to 1 Month
change in weight from baseline to 1-month followup (in kg); assessed objectively via e-scale
Time frame: baseline, 1 month
Body Weight From Baseline to 3 Months
change in weight from baseline to 3-month followup (in kg); assessed objectively via e-scale
Time frame: baseline, 3 month
Clinically Significant Weight Loss
proportion of participants achieving ≥5% weight loss from baseline
Time frame: 6 months
BMI Change From Baseline to 6 Months
change in BMI from baseline to 6-month followup (in kg/m\^2); computed from self-reported height and e-scale weight
Time frame: baseline, 6 months
Caloric Intake Change From Baseline to 6 Months
change in caloric intake from baseline to 6-month followup (in kcal); assessed using Automated 24-Hour (ASA-24) Dietary Assessment Tool (2 separate 24hr diet recalls at each time point: 1 week day, 1 weekend day)
Time frame: baseline, 6 months
Physical Activity Change From Baseline to 6 Months
change in physical activity from baseline to 6-month followup; assessed using Godin Leisure-Time Exercise Questionnaire (GLTEQ)'s MVPA Score Index. The GLTEQ is a self-report measure that assesses a typical week's frequency of engaging in different types of exercise for at least 15 minutes. Minimum score is 0; there is no maximum score. Higher scores indicate more frequent moderate-to-vigorous physical activity. Scores ≥ 24 indicate "active" while scores \< 24 indicate "insufficiently active."
Time frame: baseline, 6 months
Engagement in Self-monitoring Dietary Intake
average percent of days in the 6-month intervention of self-monitoring dietary intake; assessed objectively via digital health tools (mobile app)
Time frame: 6 months of the intervention
Engagement in Self-monitoring Weight
average percent of days in the 6-month intervention of self-monitoring weight; assessed objectively via digital health tools (e-scale)
Time frame: 6 months of the intervention
Engagement in Self-monitoring Steps
average percent of days in the 6-month intervention of self-monitoring steps; assessed objectively via digital health tools (activity monitor)
Time frame: 6 months of the intervention
Participants were enrolled in the Spark trial between September 22, 2023 and November 18, 2024. The trial was fully remote, with recruitment of adults across the United States.
| Milestone | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 |
|---|---|---|---|---|---|---|---|---|
| Started | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Completed | 21 | 20 | 21 | 19 | 19 | 19 | 21 | 18 |
| Not completed | 1 | 2 | 1 | 3 | 3 | 3 | 1 | 4 |
change in weight from baseline to 6-month followup (in kg); assessed objectively via e-scale
| kg | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| Body Weight Change From Baseline to 6 Months | -4.5 ± 5.9 | -1.9 ± 5.0 | -2.9 ± 6.0 | -3.4 ± 5.2 | -3.6 ± 5.5 | -2.8 ± 5.7 |
change in weight from baseline to 1-month followup (in kg); assessed objectively via e-scale
| kg | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| Body Weight From Baseline to 1 Month | -1.7 ± 1.9 | -0.6 ± 2.4 | -1.2 ± 2.1 | -1.1 ± 2.3 | -1.6 ± 2.3 | -0.7 ± 2.0 |
change in weight from baseline to 3-month followup (in kg); assessed objectively via e-scale
| kg | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| Body Weight From Baseline to 3 Months | -3.0 ± 4.0 | -1.5 ± 3.6 | -2.3 ± 4.0 | -2.2 ± 3.8 | -2.8 ± 3.7 | -1.7 ± 4.0 |
proportion of participants achieving ≥5% weight loss from baseline
| Participants | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| Clinically Significant Weight Loss | 43 | 25 | 33 | 35 | 37 | 31 |
change in BMI from baseline to 6-month followup (in kg/m\^2); computed from self-reported height and e-scale weight
| kg/m^2 | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| BMI Change From Baseline to 6 Months | -1.6 ± 2.0 | -0.6 ± 1.7 | -1.0 ± 2.0 | -1.2 ± 1.8 | -1.3 ± 1.9 | -0.9 ± 2.0 |
change in caloric intake from baseline to 6-month followup (in kcal); assessed using Automated 24-Hour (ASA-24) Dietary Assessment Tool (2 separate 24hr diet recalls at each time point: 1 week day, 1 weekend day)
| kcal | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| Caloric Intake Change From Baseline to 6 Months | -461.8 ± 771.3 | -274.2 ± 557.4 | -382.4 ± 658.1 | -349.2 ± 692.9 | -426.3 ± 732.0 | -304.4 ± 609.8 |
change in physical activity from baseline to 6-month followup; assessed using Godin Leisure-Time Exercise Questionnaire (GLTEQ)'s MVPA Score Index. The GLTEQ is a self-report measure that assesses a typical week's frequency of engaging in different types of exercise for at least 15 minutes. Minimum score is 0; there is no maximum score. Higher scores indicate more frequent moderate-to-vigorous physical activity. Scores ≥ 24 indicate "active" while scores \< 24 indicate "insufficiently active."
| units on a scale | Self-Monitoring Diet: Yes | Self-Monitoring Diet: No | Self-Monitoring Steps: Yes | Self-Monitoring Steps: No | Self-Monitoring Weight: Yes | Self-Monitoring Weight: No |
|---|---|---|---|---|---|---|
| Physical Activity Change From Baseline to 6 Months | 4.8 ± 22.3 | 2.3 ± 16.2 | 6.7 ± 18.8 | 0.5 ± 19.5 | 3.8 ± 18.2 | 3.3 ± 20.5 |
average percent of days in the 6-month intervention of self-monitoring dietary intake; assessed objectively via digital health tools (mobile app)
| % of days in the 6-month intervention | Self-Monitoring Diet: Yes |
|---|---|
| Engagement in Self-monitoring Dietary Intake | 48.1 (14.7 to 82.6) |
average percent of days in the 6-month intervention of self-monitoring weight; assessed objectively via digital health tools (e-scale)
| % of days in the 6-month intervention | Self-Monitoring Weight: Yes |
|---|---|
| Engagement in Self-monitoring Weight | 76.4 (33.0 to 94.1) |
average percent of days in the 6-month intervention of self-monitoring steps; assessed objectively via digital health tools (activity monitor)
| % of days in the 6-month intervention | Self-Monitoring Steps: Yes |
|---|---|
| Engagement in Self-monitoring Steps | 95.6 (65.1 to 99.0) |
Collected over From randomization until end of the 6-month intervention. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Condition 1 | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Condition 2 | 0/22 (0%) | 1/22 (4.5%) | 0/22 (0%) |
| Condition 3 | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Condition 4 | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Condition 5 | 0/22 (0%) | 0/22 (0%) | 3/22 (13.6%) |
| Condition 6 | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Condition 7 | 0/22 (0%) | 0/22 (0%) | 1/22 (4.5%) |
| Condition 8 | 0/22 (0%) | 1/22 (4.5%) | 2/22 (9.1%) |
| Event | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 |
|---|---|---|---|---|---|---|---|---|
| HyperthyroidismEndocrine disorders | 0/22 | 1/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 |
| Lung cancer with hospitalizationNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 |
| Event | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 |
|---|---|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 1/22 | 0/22 |
| Disordered eatingPsychiatric disorders | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 0/22 | 0/22 |
| Unspecified, unrelated health issueGeneral disorders | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 | 0/22 | 0/22 |
| Strep throatRespiratory, thoracic and mediastinal disorders | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 | 0/22 |
| Skin irritation from activity trackerSkin and subcutaneous tissue disorders | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 |
| Unspecified illness due to severe stress from personal matterPsychiatric disorders | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 0/22 | 1/22 |
| Age, Continuous(years) | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 39.7 ± 20.0 | 48.9 ± 19.7 | 42.6 ± 19.5 | 43.3 ± 19.3 | 46.0 ± 19.1 | 44.6 ± 18.9 | 46.8 ± 18.7 | 46.1 ± 18.5 | 44.7 ± 15.3 |
| Sex: Female, Male(Participants) | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 128 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 48 |
| Race (NIH/OMB)(Participants) | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Asian | 6 | 1 | 3 | 1 | 3 | 1 | 4 | 2 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 4 | 7 | 2 | 5 | 2 | 3 | 30 |
| White | 12 | 16 | 13 | 13 | 13 | 15 | 13 | 15 | 110 |
| More than one race | 1 | 1 | 2 | 1 | 3 | 1 | 2 | 1 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 4 | 1 | 2 | 3 | 4 | 4 | 27 |
| Not Hispanic or Latino | 18 | 17 | 18 | 21 | 20 | 19 | 18 | 18 | 149 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Weight(kg) | Condition 1 | Condition 2 | Condition 3 | Condition 4 | Condition 5 | Condition 6 | Condition 7 | Condition 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 88.2 ± 32.5 | 85.5 ± 32.2 | 90.7 ± 31.9 | 89.4 ± 31.7 | 91.5 ± 31.4 | 96.9 ± 31.1 | 95.1 ± 30.8 | 86.6 ± 30.6 | 90.5 ± 17.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Once the study data have undergone final data cleaning, analysis, and planned publications, the investigators will make the final data collected as part of the proposed research available in electronic form to researchers who request them. Researchers will be asked to submit a data request in writing to the Principal Investigator so that the requested data can be made available while protecting the confidentiality of study participants and ensuring that the proposed research questions do not overlap with planned publication development by the project research team or other groups. The requested dataset will be free of identifiers that would permit linkages to individual research participants. The requestor must agree to maintain the privacy and confidentiality of the data and must indicate how they plan to store the data to demonstrate compliance with secure computing. All publications that emerge from this award will be publicly available via PubMed Central.
Ran from Sep 2023 to primary completion in Jun 2025, 20 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 20 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.